Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.

Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola F, Hwu P, Grimm E, Radvanyi L.

Cancer Immunol Res. 2016 Nov;4(11):983-994. Epub 2016 Oct 3.

2.

Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.

Sim GC, Wu S, Jin L, Hwu P, Radvanyi LG.

Oncotarget. 2016 Jun 14;7(24):36074-36091. doi: 10.18632/oncotarget.8683.

3.

Multicystic dedifferentiated retroperitoneal liposarcoma: tumour cyst fluid analysis and implications for management.

Khoury M, Sim GC, Harao M, Radvanyi L, Amini B, Benjamin RS, Pisters PW, Pollock RE, Tseng WW.

BMJ Case Rep. 2015 Jul 8;2015. pii: bcr2015211218. doi: 10.1136/bcr-2015-211218.

4.

Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.

Tseng WW, Malu S, Zhang M, Chen J, Sim GC, Wei W, Ingram D, Somaiah N, Lev DC, Pollock RE, Lizée G, Radvanyi L, Hwu P.

Sarcoma. 2015;2015:547460. doi: 10.1155/2015/547460. Epub 2015 Jan 29.

5.

The IL-2 cytokine family in cancer immunotherapy.

Sim GC, Radvanyi L.

Cytokine Growth Factor Rev. 2014 Aug;25(4):377-90. doi: 10.1016/j.cytogfr.2014.07.018. Epub 2014 Aug 1. Review.

PMID:
25200249
6.

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.

Sim GC, Chacon J, Haymaker C, Ritthipichai K, Singh M, Hwu P, Radvanyi L.

BioDrugs. 2014 Oct;28(5):421-37. doi: 10.1007/s40259-014-0097-y. Review.

PMID:
24890028
7.

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients.

Sim GC, Martin-Orozco N, Jin L, Yang Y, Wu S, Washington E, Sanders D, Lacey C, Wang Y, Vence L, Hwu P, Radvanyi L.

J Clin Invest. 2014 Jan;124(1):99-110.

8.

Comparing the ability of freshly generated and cryopreserved dendritic cell vaccines to inhibit growth of breast cancer in a mouse model.

Radhakrishnan AK, Sim GC, Cheong SK.

Biores Open Access. 2012 Oct;1(5):239-46. doi: 10.1089/biores.2012.0229.

9.

Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.

Paschen A, Sucker A, Hill B, Moll I, Zapatka M, Nguyen XD, Sim GC, Gutmann I, Hassel J, Becker JC, Steinle A, Schadendorf D, Ugurel S.

Clin Cancer Res. 2009 Aug 15;15(16):5208-15. doi: 10.1158/1078-0432.CCR-09-0886. Epub 2009 Aug 11.

10.

Experimental production of clinical-grade dendritic cell vaccine for acute myeloid leukemia.

Tan YF, Sim GC, Habsah A, Leong CF, Cheong SK.

Malays J Pathol. 2008 Dec;30(2):73-9.

Supplemental Content

Support Center